AstraZeneca Pharma India Limited has launched Fasenra™ in India on April 20, 2021.
Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
The company had earlier received Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra™).
Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.3888 as compared to the previous close of Rs. 3590.75. The total number of shares traded during the day was 34234 in over 5745 trades.
The stock hit an intraday high of Rs. 3971 and intraday low of 3713.5. The net turnover during the day was Rs. 132652656.